Skip to main content
AHCO
NASDAQ Industrial Applications And Services

AdaptHealth Sells Diabetes Health Business to Cardinal Health for $235M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.17
Mkt Cap
$1.494B
52W Low
$8.505
52W High
$13.43
52W Position info
31% above low
Off High info
17% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AHCO sits 31% above its 52-week low of $8.505.

Summary

AdaptHealth Corp. has entered into a definitive agreement to sell its Diabetes Health business to Cardinal Health for $235 million in cash, a move to refocus on its core sleep and respiratory segments and accelerate deleveraging.


Key Events · M&A and Partnerships · AHCO

  • Diabetes Health Business Sold for $235M

    AdaptHealth signed an asset purchase agreement on July 19, 2026, to sell substantially all assets of its Diabetes Health business to RGH Enterprises, LLC, a Cardinal Health subsidiary, for $235 million in cash, subject to a net working capital adjustment.

  • Strategic Portfolio Reshaping

    The divestiture is the most significant step in a multi-year effort to focus on core sleep, respiratory, and home medical equipment businesses, with the Diabetes unit to be reported as a discontinued operation.

  • Capital Allocation and Deleveraging

    Proceeds will be used for reinvestment in core businesses and debt reduction, accelerating AdaptHealth's deleveraging trajectory and strengthening its balance sheet.

  • Transaction Structure and Protections

    The deal includes an $8 million adjustment escrow and an $18.8 million indemnification escrow. A $9.4 million termination fee is payable by the buyer if the deal fails due to antitrust clearance issues.


Analysis · AHCO · Industrial Applications And Services

AdaptHealth is divesting its Diabetes Health business to Cardinal Health for $235 million in cash, a deal that sharpens its focus on core sleep and respiratory segments while providing capital for debt reduction. The sale represents a significant portfolio reshaping — the Diabetes unit is being treated as a discontinued operation going forward. The transaction is subject to HSR clearance and other customary conditions, with a $9.4 million termination fee payable by the buyer if antitrust clearance fails. For a company with a market cap around $1.5 billion, this is a material asset sale that will meaningfully alter its revenue mix and balance sheet.

At the time of this filing, AHCO was trading at $11.17 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.51 to $13.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AHCO - Latest Insights

AHCO
Jul 20, 2026, 4:37 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
AHCO
Jul 07, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
AHCO
Jul 02, 2026, 4:57 PM EDT
Source: Reuters
Importance Score:
8
AHCO
Jul 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
AHCO
May 05, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
8